SCHEMBL15214836

SCHEMBL15214836

CN1CCN(c2ccc(OC(=O)C3CCC(C4CCCCC4)CC3)cc2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.48
KMT2A Q03164 3/20 0.48
HTT P42858 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
GAA P10253 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
ELANE P08246 2/20 0.44
POLB P06746 1/20 0.44
MAPT P10636 3/20 0.44
GFER P55789 1/20 0.44
ABL1 P00519 1/20 0.43
HDAC3 O15379 2/20 0.43
HDAC8 Q9BY41 2/20 0.43
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
DDB1 Q16531 1/20 0.41
CRBN Q96SW2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP3A4 P08684 1/20 0.41
HRH3 Q9Y5N1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16744174 0.90 GAA (0.45) SMN1; SMN2KMT2AHTTTDP1GAA
SCHEMBL15214806 0.88 THRB (0.50) SMN1; SMN2KMT2AHTTTDP1GAA
SCHEMBL15214811 0.85 THRB (0.47) SMN1; SMN2KMT2AHTTTDP1GAA
SCHEMBL12125160 0.82 MAPT (0.44) KMT2AHTTGAANPSR1MAPT
SCHEMBL26038607 0.82 KMT2A (0.69) SMN1; SMN2KMT2AHTTTDP1GAA
SCHEMBL9973048 0.81 MAPT (0.41) SMN1; SMN2KMT2AHTTTDP1GAA
SCHEMBL12125162 0.80 FAAH (0.45) SMN1; SMN2KMT2AHTTTDP1GAA
SCHEMBL12125161 0.77 FAAH (0.43) SMN1; SMN2KMT2AHTTTDP1GAA
SCHEMBL26545208 0.75 ELANE (0.63) SMN1; SMN2KMT2AHTTTDP1GAA
SCHEMBL18436510 0.74 KMT2A (0.57) SMN1; SMN2KMT2AHTTTDP1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9630902-B2 Method of preparing fused ring indeno compounds TRANSITIONS OPTICAL, INC. (US) 2017-04-25 US disclosed
US-20160209561-A1 Photochromic Articles That Include Photochromic-Dichroic Materials TRANSITIONS OPTICAL, INC. 2016-07-21 US disclosed
US-9334439-B2 Photochromic articles that include photochromic-dichroic materials TRANSITIONS OPTICAL, INC. (US) 2016-05-10 US disclosed
EP-2652553-B1 PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS TRANSITIONS OPTICAL INC (US) 2016-04-06 EP disclosed
US-20160060205-A1 Method Of Preparing Fused Ring Indeno Compounds TRANSITIONS OPTICAL, INC. 2016-03-03 US disclosed
US-9206151-B2 Method of preparing fused ring indeno compounds TRANSITIONS OPTICAL, INC. (US) 2015-12-08 US disclosed
US-9051332-B1 Photochromic indeno-fused ring pyran compounds TRANSITIONS OPTICAL, INC. (US) 2015-06-09 US disclosed
WO-2015077141-A1 FUSED RING INDENO COMPOUNDS FOR PREPARATION OF PHOTOCHROMIC COMPOUNDS TRANSITIONS OPTICAL, INC. (US) 2015-05-28 WO disclosed
WO-2015077264-A1 PHOTOCHROMIC INDENO-FUSED RING PYRAN COMPOUNDS TRANSITIONS OPTICAL, INC. (US) 2015-05-28 WO disclosed
US-20150141662-A1 Method Of Preparing Fused Ring Indeno Compounds TRANSITIONS OPTICAL, INC. (US) 2015-05-21 US disclosed
US-20150141661-A1 Photochromic Indeno-Fused Ring Pyran Compounds TRANSITIONS OPTICAL, INC. (US) 2015-05-21 US disclosed
US-20150141663-A1 Fused Ring Indeno Compounds For Preparation Of Photochromic Compounds TRANSITIONS OPTICAL, INC. (US) 2015-05-21 US disclosed
US-9029565-B1 Fused ring indeno compounds for preparation of photochromic compounds TRANSITIONS OPTICAL, INC. (US) 2015-05-12 US disclosed
US-20140272468-A1 PHOTOCHROMIC ARTICLES THAT INCLUDE PHOTOCHROMIC-DICHROIC MATERIALS TRANSITIONS OPTICAL, INC. (US) 2014-09-18 US disclosed
US-8582192-B2 Polarizing photochromic articles TRANSITIONS OPTICAL, INC. (US) 2013-11-12 US disclosed
US-8518546-B2 Photochromic compounds and compositions TRANSITIONS OPTICAL, INC. (US) 2013-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150141662-A1 Method Of Preparing Fused Ring Indeno Compounds INHA, INTS9, CA9 SMN1; SMN2 4807/4885KMT2A 1445/4885HTT 2718/4885
US-20150141663-A1 Fused Ring Indeno Compounds For Preparation Of Photochromic Compounds IPO5, INCENP, NQO1 SMN1; SMN2 4816/4885KMT2A 1702/4885HTT 789/4885
US-20160060205-A1 Method Of Preparing Fused Ring Indeno Compounds INHA, INTS9, CA9 SMN1; SMN2 4807/4885KMT2A 1445/4885HTT 2718/4885
US-20150141661-A1 Photochromic Indeno-Fused Ring Pyran Compounds INF2, INCENP, RB1 SMN1; SMN2 4643/4885KMT2A 1384/4885HTT 2883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.